DBV Technologies And CEA Conclude A Scientific Cooperation To Investigate Epigenetic Modulation In Epicutaneous Immunotherapy
4/9/2014 8:49:18 AM
BAGNEUX, France, April 9, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of allergies, announced today a research collaboration agreement with the French National Genotyping Center (CNG) at the French Alternative energies and atomic energy commission (CEA). Dr. J. Tost's team at CNG uses novel technologies to analyze gene regulation and epigenetics, specifically DNA methylation. DBV and CEA/CNG will collaborate to characterize the epigenetic modifications induced by DBV's proprietary epicutaneous immunotherapy (EPITTM). The overall goal of the research is to understand the treatment maintenance effect over time and the predictive value of response to EPITTM treatment using Viaskin.
Help employers find you! Check out all the jobs and post your resume.
comments powered by